Randomized Controlled Trial of Diclofenac Sodium Gel in Knee Osteoarthritis

H. Richard Barthel, Douglas Haselwood, Selden Longley, Morris S. Gold, Roy D Altman

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Objectives: Nonsteroidal anti-inflammatory drugs have dose-related adverse effects. Topical nonsteroidal anti-inflammatory drugs may offer local efficacy with low systemic drug levels. This study assessed the efficacy and safety of topical diclofenac sodium 1% gel (DSG) in mild to moderate symptomatic knee osteoarthritis. Methods: In a randomized, double-blind, vehicle-controlled trial, 492 adults aged ≥35 years with symptomatic knee osteoarthritis of ≥6 months' duration were randomized to DSG 4 g (n = 254) or vehicle (n = 238) 4 times daily for 12 weeks. Primary efficacy outcomes at week 12 were the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale, WOMAC physical function subscale, and global rating of disease. Secondary outcomes included these outcomes assessed after 1, 4, and 8 weeks, and pain on movement assessed using a 100-mm visual analog scale. All adverse events were recorded. Results: At week 12, the DSG group had significant decreases versus the vehicle group in mean WOMAC pain (P = 0.01), mean WOMAC physical function (P = 0.001), and mean global rating of disease (P <0.001). Efficacy outcomes significantly favored DSG versus vehicle beginning at week 1. Application site reactions occurred in 5.1% and 2.5% of patients in the DSG and vehicle groups, respectively. The incidence of gastrointestinal disorders was 5.9% with DSG and 5.0% with vehicle. Conclusions: Over a 3-month treatment period, topical treatment with DSG achieved statistically and clinically significant improvements of pain and measures of physical function in patients with knee osteoarthritis.

Original languageEnglish (US)
Pages (from-to)203-212
Number of pages10
JournalSeminars in Arthritis and Rheumatism
Volume39
Issue number3
DOIs
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Knee Osteoarthritis
Diclofenac
Randomized Controlled Trials
Gels
Pain
Anti-Inflammatory Agents
Pharmaceutical Preparations
Ontario
Visual Analog Scale
Osteoarthritis
Safety
Incidence
Therapeutics

Keywords

  • diclofenac sodium
  • nonsteroidal anti-inflammatory drugs
  • osteoarthritis
  • topical administration

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Cite this

Randomized Controlled Trial of Diclofenac Sodium Gel in Knee Osteoarthritis. / Barthel, H. Richard; Haselwood, Douglas; Longley, Selden; Gold, Morris S.; Altman, Roy D.

In: Seminars in Arthritis and Rheumatism, Vol. 39, No. 3, 12.2009, p. 203-212.

Research output: Contribution to journalArticle

Barthel, H. Richard ; Haselwood, Douglas ; Longley, Selden ; Gold, Morris S. ; Altman, Roy D. / Randomized Controlled Trial of Diclofenac Sodium Gel in Knee Osteoarthritis. In: Seminars in Arthritis and Rheumatism. 2009 ; Vol. 39, No. 3. pp. 203-212.
@article{34303cbd5afe4a2ebd4f87738264c651,
title = "Randomized Controlled Trial of Diclofenac Sodium Gel in Knee Osteoarthritis",
abstract = "Objectives: Nonsteroidal anti-inflammatory drugs have dose-related adverse effects. Topical nonsteroidal anti-inflammatory drugs may offer local efficacy with low systemic drug levels. This study assessed the efficacy and safety of topical diclofenac sodium 1{\%} gel (DSG) in mild to moderate symptomatic knee osteoarthritis. Methods: In a randomized, double-blind, vehicle-controlled trial, 492 adults aged ≥35 years with symptomatic knee osteoarthritis of ≥6 months' duration were randomized to DSG 4 g (n = 254) or vehicle (n = 238) 4 times daily for 12 weeks. Primary efficacy outcomes at week 12 were the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale, WOMAC physical function subscale, and global rating of disease. Secondary outcomes included these outcomes assessed after 1, 4, and 8 weeks, and pain on movement assessed using a 100-mm visual analog scale. All adverse events were recorded. Results: At week 12, the DSG group had significant decreases versus the vehicle group in mean WOMAC pain (P = 0.01), mean WOMAC physical function (P = 0.001), and mean global rating of disease (P <0.001). Efficacy outcomes significantly favored DSG versus vehicle beginning at week 1. Application site reactions occurred in 5.1{\%} and 2.5{\%} of patients in the DSG and vehicle groups, respectively. The incidence of gastrointestinal disorders was 5.9{\%} with DSG and 5.0{\%} with vehicle. Conclusions: Over a 3-month treatment period, topical treatment with DSG achieved statistically and clinically significant improvements of pain and measures of physical function in patients with knee osteoarthritis.",
keywords = "diclofenac sodium, nonsteroidal anti-inflammatory drugs, osteoarthritis, topical administration",
author = "Barthel, {H. Richard} and Douglas Haselwood and Selden Longley and Gold, {Morris S.} and Altman, {Roy D}",
year = "2009",
month = "12",
doi = "10.1016/j.semarthrit.2009.09.002",
language = "English (US)",
volume = "39",
pages = "203--212",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Randomized Controlled Trial of Diclofenac Sodium Gel in Knee Osteoarthritis

AU - Barthel, H. Richard

AU - Haselwood, Douglas

AU - Longley, Selden

AU - Gold, Morris S.

AU - Altman, Roy D

PY - 2009/12

Y1 - 2009/12

N2 - Objectives: Nonsteroidal anti-inflammatory drugs have dose-related adverse effects. Topical nonsteroidal anti-inflammatory drugs may offer local efficacy with low systemic drug levels. This study assessed the efficacy and safety of topical diclofenac sodium 1% gel (DSG) in mild to moderate symptomatic knee osteoarthritis. Methods: In a randomized, double-blind, vehicle-controlled trial, 492 adults aged ≥35 years with symptomatic knee osteoarthritis of ≥6 months' duration were randomized to DSG 4 g (n = 254) or vehicle (n = 238) 4 times daily for 12 weeks. Primary efficacy outcomes at week 12 were the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale, WOMAC physical function subscale, and global rating of disease. Secondary outcomes included these outcomes assessed after 1, 4, and 8 weeks, and pain on movement assessed using a 100-mm visual analog scale. All adverse events were recorded. Results: At week 12, the DSG group had significant decreases versus the vehicle group in mean WOMAC pain (P = 0.01), mean WOMAC physical function (P = 0.001), and mean global rating of disease (P <0.001). Efficacy outcomes significantly favored DSG versus vehicle beginning at week 1. Application site reactions occurred in 5.1% and 2.5% of patients in the DSG and vehicle groups, respectively. The incidence of gastrointestinal disorders was 5.9% with DSG and 5.0% with vehicle. Conclusions: Over a 3-month treatment period, topical treatment with DSG achieved statistically and clinically significant improvements of pain and measures of physical function in patients with knee osteoarthritis.

AB - Objectives: Nonsteroidal anti-inflammatory drugs have dose-related adverse effects. Topical nonsteroidal anti-inflammatory drugs may offer local efficacy with low systemic drug levels. This study assessed the efficacy and safety of topical diclofenac sodium 1% gel (DSG) in mild to moderate symptomatic knee osteoarthritis. Methods: In a randomized, double-blind, vehicle-controlled trial, 492 adults aged ≥35 years with symptomatic knee osteoarthritis of ≥6 months' duration were randomized to DSG 4 g (n = 254) or vehicle (n = 238) 4 times daily for 12 weeks. Primary efficacy outcomes at week 12 were the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale, WOMAC physical function subscale, and global rating of disease. Secondary outcomes included these outcomes assessed after 1, 4, and 8 weeks, and pain on movement assessed using a 100-mm visual analog scale. All adverse events were recorded. Results: At week 12, the DSG group had significant decreases versus the vehicle group in mean WOMAC pain (P = 0.01), mean WOMAC physical function (P = 0.001), and mean global rating of disease (P <0.001). Efficacy outcomes significantly favored DSG versus vehicle beginning at week 1. Application site reactions occurred in 5.1% and 2.5% of patients in the DSG and vehicle groups, respectively. The incidence of gastrointestinal disorders was 5.9% with DSG and 5.0% with vehicle. Conclusions: Over a 3-month treatment period, topical treatment with DSG achieved statistically and clinically significant improvements of pain and measures of physical function in patients with knee osteoarthritis.

KW - diclofenac sodium

KW - nonsteroidal anti-inflammatory drugs

KW - osteoarthritis

KW - topical administration

UR - http://www.scopus.com/inward/record.url?scp=70449650389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449650389&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2009.09.002

DO - 10.1016/j.semarthrit.2009.09.002

M3 - Article

C2 - 19932833

AN - SCOPUS:70449650389

VL - 39

SP - 203

EP - 212

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 3

ER -